TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a
global company specializing in disinfection and decontamination,
utilizing its premier Binary Ionization Technology (BIT) platform
through its SteraMist brand of products, announced the
implementation of SteraMist technology into four Catalent
facilities, and a planned expansion into a fifth location.
Catalent is one of the most established pharmaceutical partners
within TOMI’s Life Sciences division. In October 2018, the
company’s first purchase order was for an Environment System and a
Surface Unit. Shortly after, in May 2019, having experienced
firsthand the direct advantages of SteraMist, Catalent purchased
six additional Environment Systems and an additional Surface Unit
for its BioPark and Harmans facilities. Recently, TOMI received an
additional six-figure purchase order from Catalent for additional
SteraMist units. Catalent has also turned to TOMI’s iHP Corporate
Service team to decontaminate one of their facilities, resulting in
additional revenue. Furthermore, Catalent is planning to install a
Custom Engineered System (CES) for use within their material
airlocks.
Catalent has also expressed interest in purchasing several
SteraMist Select Plus units for their facilities once testing is
completed. The SteraMist Select Plus is currently under development
by TOMI as a hybrid product consisting of the Company’s current
Surface Select and Environment systems. The unit will allow for
enhanced flexibility by using a single applicator to decontaminate
full-room to small-space volume while maintaining the size of the
current Surface unit with more robust process controls.
David Small, in Catalent’s validation department, explains: “We
successfully used the system on a bacteriophage. Using the iHP to
inactivate a nanometer-sized bacteriophage, to our knowledge had
never been tried. The system efficiently and effectively resolved
the bacteriophage contamination. I am a strong proponent of the
SteraMist systems and believe our continued use of the technology
and partnership with TOMI will continue to yield a line of products
that are superior, safer, and more effective than alternatives in
the marketplace.”
“This is one of our many customers within the life sciences
expanding their potential and streamlining operations with
SteraMist technology,” Elissa J. (E.J.) Shane, TOMI’s Chief
Operating Officer states. “After the initial purchase proved
SteraMist’s ease-of-implementation into facilities while validating
results against the most dangerous pathogens, we were given the
green light to expand. The process has been lengthy, but the
resulting strong partnerships are worthwhile.”
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery
technologies, development, and manufacturing solutions for drugs,
biologics, cell and gene therapies, and consumer health products.
With over 85 years serving the industry, Catalent has proven
expertise in bringing more customer products to market faster,
enhancing product performance and ensuring reliable global clinical
and commercial product supply. Catalent employs approximately
15,000 people, including around 2,400 scientists and technicians,
at more than 45 facilities, and in fiscal year 2020 generated over
$3 billion in annual revenue. Catalent is headquartered in
Somerset, New Jersey.
For more information, visit www.catalent.com.
ABOUT TOMI™ Environmental Solutions, Inc.: Innovating
for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a
global decontamination and infection prevention company, providing
environmental solutions for indoor surface disinfection through the
manufacturing, sales and licensing of its premier Binary Ionization
Technology® (BIT™) platform. Invented under a defense grant in
association with the Defense Advanced Research Projects Agency
(DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a
low percentage Hydrogen Peroxide as its only active ingredient to
produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by
the SteraMist® brand of products, iHP™ produces a germ-killing
aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of
commercial structures, including, but not limited to, hospitals and
medical facilities, cruise ships, office buildings, hotel and motel
rooms, schools, restaurants, meat and produce processing
facilities, military barracks, police and fire departments, and
athletic facilities. TOMI products and services have also been used
in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for
its clients and is a member in good standing with The American
Biological Safety Association, The American Association of Tissue
Banks, Association for Professionals in Infection Control and
Epidemiology, Society for Healthcare Epidemiology of America,
America Seed Trade Association, and The Restoration Industry
Association.
For additional information, please visit
http://www.tomimist.com/ or contact us at info@tomimist.com.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute
“forward-looking statements” as defined in the Private Securities
Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking
statements are identified by such words and phrases as “we expect,”
“expected to,” “estimates,” “estimated,” “current outlook,” “we
look forward to,” “would equate to,” “projects,” “projections,”
“projected to be,” “anticipates,” “anticipated,” “we believe,”
“could be,” and other similar phrases. All statements addressing
operating performance, events, or developments that we expect or
anticipate will occur in the future, including statements relating
to revenue growth, earnings, earnings-per-share growth, or similar
projections, are forward-looking statements within the meaning of
the Reform Act. They are forward-looking, and they should be
evaluated in light of important risk factors that could cause our
actual results to differ materially from our anticipated results.
The information provided in this document is based upon the facts
and circumstances known at this time. We undertake no obligation to
update these forward-looking statements after the date of this
release.
INVESTOR RELATIONS CONTACT
IMS INVESTOR RELATIONSJohn Nesbett/Jen
Belodeau203-972-9200jnesbett@imsinvestorrelations.com
TOMI Environmental Solut... (NASDAQ:TOMZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
TOMI Environmental Solut... (NASDAQ:TOMZ)
Historical Stock Chart
From Apr 2023 to Apr 2024